Alliance Pharma plc (AIM: APH), the emerging speciality pharmaceutical company, is pleased to announce the following senior management positions.

Dr Veronica Farrell-Lecomte has joined Alliance Pharma as Director of Regulatory Affairs. This appointment boosts the resources behind Alliance's proprietary development projects, which are currently going through their clinical development programmes. Its two in-house development programmes are Posidorm™, a surge-sustained formulation of melatonin for use in sleep disorders and Isprelor™, an intra-vaginal formulation of misoprostol for the induction of labour.

Veronica has a PhD in molecular biology and immunology from Université Joseph Fourier, Grenoble.  Veronica’s career to date spans more than twenty years of research,  clinical project management, regulatory assessment and regulatory management  for organisations such as the UK Central Veterinary Laboratory, the UK Department of Health, the Organisation for Economic Co-operation and Development, Aventis Pharma, Orphan Europe and a Hoffman La Roche development at the Universitatsklinikum, Leipzig.

Sam Madden, previously Director of Regulatory Affairs, now takes on the new role of Director of  Acquisitions Integration, to plan and implement the transfer of acquired brands into Alliance’s operations.

Commenting on the news, John Dawson, Alliance Pharma’s Chief Executive, said:
"I am very pleased to welcome Veronica into the Alliance Pharma team.  Veronica brings a wealth of regulatory, clinical development and project management experience to the company and will play a key role in our important clinical development programmes. Both Posidorm and Isprelor, are important elements in generating long-term shareholder value in the company.  Additionally the focussed resource now applied to the integration of brand acquisitions gives an extra boost to that equally important source of growth."

For further information:
Alliance Pharma plc               + 44 (0) 1249 466966
John Dawson, Chief Executive 
Maddy Scott, Finance Director 
www.alliancepharma.co.uk

Buchanan Communications        + 44 (0) 20 7466 5000
Mark Court/Lisa Baderoon/Rebecca Skye Dietrich 

Notes to editors
About Alliance Pharma
Alliance Pharma, founded in 1996, is an AIM listed emerging speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The company has a strong track record of acquiring the rights to established niche brands and owns, or shares, the rights to 30 branded pharmaceutical products and continues to explore opportunities to expand the range.

Alliance Pharma's products are prescribed in the treatment of a wide range of conditions and include brands used in periodontitis (a serious gum disease), the prevention of heart disease, in Parkinson's disease, in nutrition, in nasal infections, in the treatment of dermatological conditions and in childbirth.  Alliance Pharma's sales are mainly prescription driven.  Its products are distributed to hospitals directly and to pharmaceutical wholesalers which service both hospital and retail pharmacies with their prescription requirements.

Alliance Pharma is also developing novel products for sleep disorders and the induction of labour.

Alliance Pharma joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.